 Twist Bioscience Corporation NASDAQ: TWST reported a 17 YY increase in its Q4 revenues to 37.95 million, beating the Wall Street estimate of 37.02 million, driven by strength in SynBio, NGS, biopharma businesses. The Company shipped products to approximately 2,900 customers in fiscal 2021, versus about 2,200 in fiscal 2020. 